Published in Am J Psychiatry on June 01, 2002
Amplitude of low-frequency oscillations in schizophrenia: a resting state fMRI study. Schizophr Res (2009) 2.44
Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (2010) 2.13
Modern antipsychotic drugs: a critical overview. CMAJ (2005) 1.98
Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (2010) 1.62
Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia. Biol Psychiatry (2010) 1.48
Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull (2007) 1.45
Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (2011) 1.41
Psychomotor slowing in schizophrenia. Schizophr Bull (2006) 1.36
Pathways to aggression in schizophrenia affect results of treatment. Schizophr Bull (2011) 1.18
Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. Psychopharmacology (Berl) (2007) 1.18
Is schizoaffective disorder a distinct categorical diagnosis? A critical review of the literature. Neuropsychiatr Dis Treat (2008) 1.14
The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl) (2006) 1.13
Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatr Dis Treat (2006) 1.11
Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology (Berl) (2004) 1.09
Dopamine depletion of the prefrontal cortex induces dendritic spine loss: reversal by atypical antipsychotic drug treatment. Neuropsychopharmacology (2007) 1.09
Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder. Psychiatry Res (2005) 1.07
Neurobiological correlates of violent behavior among persons with schizophrenia. Schizophr Bull (2005) 1.06
Neurocognitive functioning in patients with first-episode schizophrenia : results of a prospective 5-year follow-up study. Eur Arch Psychiatry Clin Neurosci (2006) 1.06
Voxelwise correlational analyses of white matter integrity in multiple cognitive domains in schizophrenia. Am J Psychiatry (2006) 1.05
Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder. Neuropsychiatr Dis Treat (2009) 1.01
Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: a placebo-controlled pilot study. Psychiatry Investig (2012) 0.98
Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trail of treatment with atypical antipsychotics. Eur Arch Psychiatry Clin Neurosci (2008) 0.96
Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. J Int Neuropsychol Soc (2008) 0.96
A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians. Schizophr Bull (2009) 0.94
Apolipoprotein D takes center stage in the stress response of the aging and degenerative brain. Neurobiol Aging (2014) 0.93
Cognitive deficits in psychiatric disorders: Current status. Indian J Psychiatry (2006) 0.92
Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. Eur Arch Psychiatry Clin Neurosci (2007) 0.92
Chronic nicotine improves cognitive performance in a test of attention but does not attenuate cognitive disruption induced by repeated phencyclidine administration. Psychopharmacology (Berl) (2008) 0.91
Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats. Psychopharmacology (Berl) (2011) 0.90
Changes in cerebellar functional connectivity and anatomical connectivity in schizophrenia: a combined resting-state functional MRI and diffusion tensor imaging study. J Magn Reson Imaging (2011) 0.90
The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology (Berl) (2006) 0.90
Prefrontal cortical dysfunction after overexpression of histone deacetylase 1. Biol Psychiatry (2013) 0.89
The effect of repetitive transcranial magnetic stimulation on gamma oscillatory activity in schizophrenia. PLoS One (2011) 0.89
Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. J Clin Psychiatry (2009) 0.88
Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic. Neuropsychiatr Dis Treat (2007) 0.88
Pathways Associating Childhood Trauma to the Neurobiology of Schizophrenia. Front Psychol Behav Sci (2014) 0.88
General and domain-specific neurocognitive impairments in deficit and non-deficit schizophrenia. Eur Arch Psychiatry Clin Neurosci (2011) 0.87
Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia. Psychopharmacology (Berl) (2003) 0.87
Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology (Berl) (2003) 0.87
Cognitive functioning in the early course of first-episode schizophrenia spectrum disorders: timing and patterns. Eur Arch Psychiatry Clin Neurosci (2006) 0.87
Toward a model of memory enhancement in schizophrenia: glucose administration and hippocampal function. Schizophr Bull (2007) 0.86
Effect of antipsychotics on succinate dehydrogenase and cytochrome oxidase activities in rat brain. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.86
Propranolol blocks chronic risperidone treatment-induced enhancement of spatial working memory performance of rats in a delayed matching-to-place water maze task. Psychopharmacology (Berl) (2007) 0.86
Cognitive effects of risperidone in children with autism and irritable behavior. J Child Adolesc Psychopharmacol (2008) 0.86
Cognitive effects of olanzapine treatment in schizophrenia. MedGenMed (2004) 0.85
Oculomotor and neuropsychological effects of antipsychotic treatment for schizophrenia. Schizophr Bull (2007) 0.85
Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci (2007) 0.84
Improvement and decline of cognitive function in schizophrenia over one year: a longitudinal investigation using latent growth modelling. BMC Psychiatry (2007) 0.84
Cognitive predictors of skill acquisition on social problem solving in patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci (2006) 0.84
Increased impulsivity and disrupted attention induced by repeated phencyclidine are not attenuated by chronic quetiapine treatment. Pharmacol Biochem Behav (2008) 0.84
Quetiapine reduces nocturnal urinary cortisol excretion in healthy subjects. Psychopharmacology (Berl) (2004) 0.84
Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development. Front Neurosci (2013) 0.83
GABA Targets for the Treatment of Cognitive Dysfunction in Schizophrenia. Curr Neuropharmacol (2005) 0.83
The developmental course of executive functioning in schizophrenia. Int J Dev Neurosci (2010) 0.82
Clozapine attenuates disruptions in response inhibition and task efficiency induced by repeated phencyclidine administration in the intracranial self-stimulation procedure. Eur J Pharmacol (2008) 0.82
Clozapine: Current perspective. Indian J Psychiatry (2007) 0.82
Driving simulator performance and psychomotor functions of schizophrenic patients treated with antipsychotics. Eur Arch Psychiatry Clin Neurosci (2009) 0.81
A principal component network analysis of prefrontal-limbic functional magnetic resonance imaging time series in schizophrenia patients and healthy controls. Psychiatry Res (2009) 0.81
Estrogen and comprehension of metaphoric speech in women suffering from schizophrenia: results of a double-blind, placebo-controlled trial. Schizophr Bull (2007) 0.80
Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci (2014) 0.80
Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone. Clin Psychopharmacol Neurosci (2013) 0.80
Role of quetiapine beyond its clinical efficacy in bipolar disorder: From neuroprotection to the treatment of psychiatric disorders (Review). Exp Ther Med (2015) 0.80
Ten year neurocognitive trajectories in first-episode psychosis. Front Hum Neurosci (2013) 0.79
Attention and multisensory integration of emotions in schizophrenia. Front Hum Neurosci (2013) 0.79
Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms. Psychopharmacology (Berl) (2009) 0.79
Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: An open-label clinical study. Ind Psychiatry J (2014) 0.79
Cognitive-enhancing effects of aripiprazole: a case report. Clin Pract Epidemiol Ment Health (2008) 0.79
Prototypical antipsychotic drugs protect hippocampal neuronal cultures against cell death induced by growth medium deprivation. BMC Neurosci (2006) 0.79
Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review. Neuropsychiatr Dis Treat (2016) 0.78
Prominent clinical dimension, duration of illness and treatment response in schizophrenia: a naturalistic study. Psychiatry Investig (2012) 0.77
Further characterization of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in C57BL/6 mice: role of 5-HT(2A) serotonergic and alpha (1) adrenergic antagonism. Psychopharmacology (Berl) (2008) 0.77
Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review. Neuropsychiatr Dis Treat (2014) 0.77
Cognitive Outcomes in the CATIE Schizophrenia Trial: Why do they seem different from previous results? Psychiatry (Edgmont) (2007) 0.77
Increased prolactin levels are associated with impaired processing speed in subjects with early psychosis. PLoS One (2014) 0.76
Treatment-refractory schizophrenia. Dialogues Clin Neurosci (2004) 0.76
The effects of risperidone on the cognitive performance of individuals with schizotypal personality disorder. J Clin Psychopharmacol (2009) 0.76
Reduced Prefrontal Cortex Hemodynamic Response in Adults with Methamphetamine Induced Psychosis: Relevance for Impulsivity. PLoS One (2016) 0.76
IMAGING THE BRAIN AS SCHIZOPHRENIA DEVELOPS: DYNAMIC & GENETIC BRAIN MAPS. Prim psychiatry (2002) 0.75
Response to: A Commentary on "Antipsychotic-Induced Parkinsonism is Associated with Working Memory Deficits in Schizophrenia-Spectrum Disorders". Front Behav Neurosci (2015) 0.75
Evaluation of efficacy, safety, and cognitive profile of amisulpride per se and its comparison with olanzapine in newly diagnosed schizophrenic patients in an 8-week, double-blind, single-centre, prospective clinical trial. ISRN Psychiatry (2012) 0.75
Impact of DRD2/ANKK1 and COMT Polymorphisms on Attention and Cognitive Functions in Schizophrenia. PLoS One (2017) 0.75
Developing therapeutics for schizophrenia and other psychotic disorders. NeuroRx (2005) 0.75
Managing pathologic aggression in people with psychotic disorders. J Psychiatry Neurosci (2012) 0.75
Effectiveness and tolerability of warm-supplementing kidney yang added to risperidone in improving cognitive impairment in patients with schizophrenia: An 8-week, multicenter, randomized, double-blind, placebo-controlled clinical trial. Curr Ther Res Clin Exp (2008) 0.75
Efficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, multicenter, open-label, nonrandomized study. Curr Ther Res Clin Exp (2004) 0.75
Reversal of evoked gamma oscillation deficits is predictive of antipsychotic activity with a unique profile for clozapine. Transl Psychiatry (2016) 0.75
Comparable dopamine 2 receptor occupancy. Am J Psychiatry (2002) 0.75
Cognitive burden of anticholinergic medications in psychotic disorders. Schizophr Res (2017) 0.75
Beneficial effect of atypical antipsychotics on prefrontal brain function in acute psychotic disorders. Eur Arch Psychiatry Clin Neurosci (2005) 0.75
Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes. J Psychiatr Res (2017) 0.75
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med (2006) 10.89
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry (2004) 6.40
Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet (2009) 6.13
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry (2002) 5.14
Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry (2005) 4.28
Boundary and medial shape analysis of the hippocampus in schizophrenia. Med Image Anal (2004) 4.25
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull (2003) 4.13
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry (2006) 4.12
Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry (2005) 3.78
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry (2006) 3.72
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry (2013) 3.69
Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry (2006) 3.66
Physical health monitoring of patients with schizophrenia. Am J Psychiatry (2004) 3.54
The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology (2004) 3.51
Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br J Psychiatry (2011) 3.49
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry (2008) 3.48
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry (2008) 3.30
Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry (2006) 3.28
Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry (2007) 3.26
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry (2007) 3.21
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry (2006) 3.12
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res (2005) 2.91
Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am J Psychiatry (2007) 2.90
Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry (2008) 2.86
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry (2007) 2.75
Morphometric analysis of lateral ventricles in schizophrenia and healthy controls regarding genetic and disease-specific factors. Proc Natl Acad Sci U S A (2005) 2.73
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry (2007) 2.68
Regional gray matter growth, sexual dimorphism, and cerebral asymmetry in the neonatal brain. J Neurosci (2007) 2.61
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res (2006) 2.60
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry (2003) 2.43
Barriers to employment for people with schizophrenia. Am J Psychiatry (2006) 2.42
Effectiveness of switching antipsychotic medications. Am J Psychiatry (2006) 2.38
Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron (2013) 2.32
Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry (2003) 2.24
A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry (2006) 2.23
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry (2007) 2.22
Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry (2010) 2.19
Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography. Biol Psychiatry (2005) 2.16
Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry (2005) 2.14
Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br J Psychiatry (2008) 2.10
First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res (2004) 2.06
Identifying clinically questionable psychotropic prescribing practices for medicaid recipients in new york state. Psychiatr Serv (2009) 2.05
Teaching trainees to negotiate research collaborations with industry: a mentorship model. Am J Psychiatry (2010) 2.04
Psychosocial treatment for first-episode psychosis: a research update. Am J Psychiatry (2005) 2.03
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry (2010) 1.99
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res (2008) 1.97
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res (2008) 1.95
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry (2011) 1.87
Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology (2005) 1.83
Components and correlates of family burden in schizophrenia. Psychiatr Serv (2006) 1.81
Clozapine augmentation with aripiprazole for negative symptoms. J Clin Psychiatry (2006) 1.81
Prenatal and neonatal brain structure and white matter maturation in children at high risk for schizophrenia. Am J Psychiatry (2010) 1.79
Positron emission tomography of regional brain metabolic responses to a serotonergic challenge and lethality of suicide attempts in major depression. Arch Gen Psychiatry (2003) 1.78
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry (2003) 1.76
Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry (2006) 1.74
Testosterone levels in suicide attempters with bipolar disorder. J Psychiatr Res (2012) 1.72
A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol (2010) 1.69
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry (2005) 1.68
Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry (2005) 1.66
Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry (2002) 1.66
Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am J Psychiatry (2008) 1.62
Mental disorder and violence: is there a relationship beyond substance use? Soc Psychiatry Psychiatr Epidemiol (2011) 1.62
Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study. J Am Acad Child Adolesc Psychiatry (2012) 1.62
Frontal white matter microstructure, aggression, and impulsivity in men with schizophrenia: a preliminary study. Biol Psychiatry (2002) 1.62
Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. Int J Neuropsychopharmacol (2005) 1.59
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry (2004) 1.58
The InterSePT scale for suicidal thinking reliability and validity. Schizophr Res (2003) 1.58
Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res (2011) 1.57
Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav Brain Res (2004) 1.56
What CATIE found: results from the schizophrenia trial. Psychiatr Serv (2008) 1.55
Cigarette smoking, suicidal behavior, and serotonin function in major psychiatric disorders. Am J Psychiatry (2003) 1.55
Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. J Clin Psychiatry (2015) 1.55